Beam Therapeutics Inc. — Director's Dealing 2021

Jul 3, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Beam Therapeutics Inc. (BEAM)
CIK: 0001745999
Period of Report: 2021-06-30

Reporting Person: Burrell Terry-Ann (CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-30	Common Stock	M	30000	$13.68	Acquired	54809	Direct
2021-06-30	Common Stock	S	15000	$117.00	Disposed	39809	Direct
2021-06-30	Common Stock	S	15000	$127.00	Disposed	24809	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-30	Stock Option (Right to Buy)	$13.68	M	30000	Disposed	2029-08-31	Common Stock (30000)	Direct

Footnotes

F1: The stock option exercise reported in this Form 4 was effected pursuant to a 10b5-1 trading plan.

F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F3: The option vests as to 25% on the first anniversary of the of the vesting commencement date, August 20, 2019, and at a rate of 2.78% each month thereafter until the option is fully vested.